Topics: FDA, Cancer, Drug Cost, Hepatitis C, High Cholesterol, Biologics and Biosimilars, Let's Talk About Cost
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
LTAC Teaser_1000x635.
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by the U.S. Food and Drug Administration. In the midst of all this incredible progress, spending on medicines grew just 0.6 percent in 2017, according to the new IQVIA Institute for Human Data Science “2017 Medicine Use and Spending in the U.S.” report.
This report is further evidence we don’t have to choose between innovation and affordability.
Here are four things you should know about the “2017 Medicine Use and Spending in the U.S.” report:
Learn more at LetsTalkAboutCost.org.
Topics: FDA, Cancer, Drug Cost, Hepatitis C, High Cholesterol, Biologics and Biosimilars, Let's Talk About Cost
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."